← Back to catalogue

Revitive Medic Plus

FDA UDI

Class II (US FDA UDI)

by Actegy , Ltd.

Identity

Trade Name
Revitive Medic Plus FDA UDI
Generic Name
Analgesic transcutaneous electrical nerve stimulation system FDA UDI
Device Name
Neuromuscular Electrical Stimulation and Transcutaneous Electrical Nerve Stimulation Device FDA UDI
Model / Reference
3156AD FDA UDI
Description
Neuromuscular Electrical Stimulation and Transcutaneous Electrical Nerve Stimulation Device FDA UDI

Identifiers

Catalog Number
3158 FDA UDI
Primary DI / UDI-DI
00858058005146 FDA UDI
510(k) Number
K190924 FDA UDI
FDA Product Code
NYN FDA UDI
IPF FDA UDI
GZJ FDA UDI
NUH FDA UDI
NGX FDA UDI
GMDN Term
Analgesic transcutaneous electrical nerve stimulation system FDA UDI

Classification

Device Class
Class II FDA UDI
Regulation Number
882.5890 FDA UDI
890.5850 FDA UDI
Commercial Distribution
In Commercial Distribution FDA UDI

Clinical & Handling

Sterile

No

FDA UDI

Single Use

No

FDA UDI

Implantable

No

FDA UDI

Contains Latex

No

FDA UDI

Prescription Use

No

FDA UDI

Over-the-Counter

Yes

FDA UDI

Convenience Kit

No

FDA UDI

Combination Product

No

FDA UDI

HCT/P

No

FDA UDI

Premarket Exempt

No

FDA UDI

Lot / Batch Number

No

FDA UDI

Serial Number

Yes

FDA UDI

Expiration Date

No

FDA UDI

Manufacturing Date

Yes

FDA UDI

Category: Analgesic transcutaneous electrical nerve stimulation systemPhysical therapy transcutaneous electrical stimulation system, line-powered

Revitive Medic Plus by Actegy , Ltd. — Class II — FDA UDI — listed in FDA GUDID — regulatory data on deviCERTS

Similar devices

Also classified as Physical therapy transcutaneous electrical stimulation system, line-powered.

Cleared under the same submission

Authorization Coverage (1 country)

Regulatory Authorizations

United States Pending data

FDA UDI

Is this your device? Claim it to add documentation and request validation.

Manufacturer

Manufacturer
Actegy , Ltd.

Sources (1)

  • FDA UDI e09df9e4-1eee-4758-b647-7009c2c3f1d0 37 fields · synced May 30, 2026